Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 1% procyanidin B-2 tonic significantly increased the number of total and terminal hairs on the scalp of male participants compared to a placebo after 6 months of use.

This study revealed that IP-PA1, derived from Pantoea agglomerans, promoted hair growth in mice and increased certain growth factor expressions in human cell cultures, suggesting a unique mechanism compared to traditional hair growth treatments.

This study found that a combination of Trichogen and climbazole may inhibit protease activity and increase the force required to remove human hair, suggesting potential to reduce excessive hair shedding.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This study developed a sensitive and specific method for detecting testosterone in horse hair, finding trace amounts in samples for up to five months after administering a single dose.

In this study, nine male cases of androgenetic alopecia showed marked improvement after receiving systemic dexpanthenol treatment.

In this case report, researchers identified Arthroderma vanbreuseghemii as the cause of a familial fungal infection, which was successfully treated with itraconazole and topical terbinafine cream.

This study observed that PCE-DP may improve skin pigmentation by increasing epidermal turnover and inhibiting melanin uptake and inflammation in human epidermal keratinocytes.

This paper reviews the hair color changes associated with valproic acid treatment, noting only a few reported instances of bleaching or darkening, and reports no new findings.

This study found that adding procapil to minoxidil was more effective than minoxidil alone in improving hair count, patient satisfaction, and dermatologist assessment scores for treating androgenetic alopecia over 12 months.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.

In this study, PRP injections showed comparable effectiveness to triamcinolone for alopecia areata, with a significant decrease in SALT score at one interval, and 12.5% of patients in the PRP group experienced excellent hair regrowth compared to none in the triamcinolone group.

Mutations in the P2RY5 gene cause hereditary woolly hair.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

This study identified upregulation of genes linked to fibroproliferative disorders, such as platelet-derived growth factor and collagen genes, in patients with central centrifugal cicatricial alopecia, suggesting potential therapeutic targets.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

The researchers reported that protocatechuic acid reduced melanin synthesis and enhanced antioxidant activity in cultured human hair follicle melanocytes, indicating potential for skin whitening applications.

This study found that PPAR alpha, -delta, and -gamma are expressed in human hair follicle cells, and clofibrate exhibited a beneficial effect on hair follicle survival in culture within a specific concentration range.

This paper reviews the use of tacrolimus for various conditions, noting its effectiveness in treating certain skin disorders but highlighting that some findings remain anecdotal due to limited case numbers.

This study suggests that the dipeptide Pro-Ile has FGF18-like activity, can penetrate model human epidermis, and may have potential as a cosmetic ingredient for skin and hair regulation.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.